Essential_JJ myosin_NN light_NN chain_NN as_IN a_DT target_NN for_IN caspase-3_NN in_IN failing_VBG myocardium_NN Programmed_JJ cell_NN death_NN involves_VBZ the_DT activation_NN of_IN caspase_NN proteases_NNS that_WDT can_MD mediate_VB the_DT cleavage_NN of_IN vital_JJ cytoskeletal_JJ proteins_NNS ._SENT We_PP have_VBP recently_RB reported_VBN that_IN ,_, in_IN failing_VBG cardiac_JJ myocytes_NNS ,_, caspase-3_JJ activation_NN is_VBZ associated_VBN with_IN a_DT reduction_NN in_IN contractile_JJ performance_NN ._SENT In_IN this_DT study_NN we_PP used_VBD a_DT modified_JJ yeast_NN two-hybrid_NN system_NN to_TO screen_VB for_IN caspase-3_NN interacting_VBG proteins_NNS of_IN the_DT cardiac_JJ cytoskeleton_NN ._SENT We_PP identified_VBD ventricular_JJ essential_JJ myosin_NN light_NN chain_NN (_( vMLC1_JJ )_) as_IN a_DT target_NN for_IN caspase-3_NN ._SENT By_IN sequencing_NP and_CC site-directed_JJ mutagenesis_NN ,_, a_DT noncanonical_JJ cleavage_NN site_NN for_IN caspase-3_NN was_VBD mapped_VBN to_TO the_DT C-terminal_NP DFVE135G_NP motif_NN ._SENT We_PP demonstrated_VBD that_IN vMLC1_JJ cleavage_NN in_IN failing_VBG myocardium_NN in_IN vivo_JJ is_VBZ associated_VBN with_IN a_DT morphological_JJ disruption_NN of_IN the_DT organized_JJ vMLC1_NN staining_VBG of_IN sarcomeres_NNS ,_, and_CC with_IN a_DT reduction_NN in_IN myocyte_NN contractile_JJ performance_NN ._SENT Adenoviral_JJ gene_NN transfer_NN of_IN the_DT caspase_NN inhibitor_NN p35_NN in_IN vivo_RB prevented_VBN caspase-3_JJ activation_NN and_CC vMLC1_JJ cleavage_NN ,_, with_IN positive_JJ impact_NN on_IN contractility_NN ._SENT These_DT data_NNS suggest_VBP that_IN direct_JJ cleavage_NN of_IN vMLC1_NN by_IN activated_VBN caspase-3_NN may_MD contribute_VB to_TO depression_NN of_IN myocyte_NN function_NN by_IN altering_VBG cross-bridge_NN interaction_NN between_IN myosin_NN and_CC actin_NN molecules_NNS ._SENT Therefore_RB ,_, activation_NN of_IN apoptotic_JJ pathways_NNS in_IN the_DT heart_NN may_MD lead_VB to_TO contractile_JJ dysfunction_NN before_IN cell_NN death_NN ._SENT Heart_NN failure_NN is_VBZ a_DT leading_VBG cause_NN of_IN mortality_NN that_WDT ensues_VBZ following_VBG the_DT chronic_JJ activation_NN of_IN biomechanical_JJ stress_NN pathways_NNS ,_, resulting_VBG from_IN various_JJ forms_NNS of_IN myocardial_JJ injury_NN ._SENT Histological_JJ evidence_NN of_IN apoptosis_NN has_VBZ been_VBN identified_VBN in_IN several_JJ cardiovascular_JJ disorders_NNS leading_VBG to_TO congestive_JJ heart_NN failure_NN (_( CHF_NP )_) ._SENT Myocardial_JJ apoptosis_NN represents_VBZ a_DT highly_RB complex_JJ cell_NN death_NN program_NN ,_, whose_WP$ execution_NN is_VBZ regulated_VBN by_IN the_DT caspase_NN family_NN of_IN cysteine_NN proteases_NNS ._SENT Caspase-3_NP is_VBZ a_DT key_JJ effector_NN enzyme_NN and_CC cleaves_VBZ downstream_JJ critical_JJ cellular_JJ targets_NNS involved_VBN in_IN chromatin_NN condensation_NN ,_, DNA_NN fragmentation_NN ,_, and_CC cytoskeletal_JJ destruction_NN ,_, thereby_RB expressing_VBG the_DT dramatic_JJ morphological_JJ changes_NNS of_IN apoptosis_NN ._SENT Caspase-3_JJ activation_NN has_VBZ been_VBN documented_VBN in_IN the_DT myocardium_NN of_IN end-stage_NN heart_NN failure_NN patients_NNS ,_, and_CC caspase-3_NN expression_NN is_VBZ increased_VBN in_IN patients_NNS with_IN right_JJ ventricular_JJ dysplasia_NN ,_, a_DT disease_NN associated_VBN with_IN progressive_JJ cell_NN loss_NN and_CC sudden_JJ death_NN ._SENT Recently_RB ,_, myocyte_NN apoptosis_NN ,_, assessed_VBN by_IN different_JJ biochemical_JJ hallmarks_NNS ,_, including_VBG caspase-3_JJ activity_NN ,_, has_VBZ been_VBN described_VBN in_IN pacing-induced_JJ heart_NN failure_NN models_NNS in_IN animals_NNS ,_, and_CC correlates_NNS with_IN the_DT time-dependent_JJ deterioration_NN of_IN cardiac_JJ function_NN ._SENT Moreover_RB ,_, we_PP showed_VBD that_IN caspase-3_JJ activation_NN directly_RB influences_VBZ contractile_JJ performance_NN of_IN failing_VBG ventricular_JJ myocytes_NNS ,_, and_CC can_MD be_VB corrected_VBN via_IN adenovirus-mediated_JJ gene_NN delivery_NN of_IN the_DT potent_JJ caspase_NN inhibitor_NN p35_NN with_IN a_DT positive_JJ impact_NN on_IN contractility_NN ._SENT The_DT molecular_JJ mechanism_NN by_IN which_WDT activated_VBD caspase-3_JJ causes_NNS a_DT deterioration_NN of_IN cardiac_JJ function_NN has_VBZ not_RB yet_RB been_VBN established_VBN ._SENT In_IN an_DT attempt_NN to_TO answer_VB this_DT question_NN ,_, we_PP performed_VBD a_DT screening_NN for_IN caspase-3-interacting_VBG proteins_NNS expressed_VBN in_IN the_DT heart_NN ,_, using_VBG a_DT modified_JJ yeast_NN two-hybrid_NN system_NN ._SENT We_PP identified_VBD vMLC1_JJ (_( ventricular_JJ essential_JJ myosin_NN light_NN chain_NN )_) as_IN a_DT target_NN for_IN caspase-3_NN ,_, and_CC investigated_VBD whether_IN a_DT correlation_NN between_IN caspase-3_JJ activation_NN ,_, vMLC1_JJ cleavage_NN ,_, and_CC contractile_JJ performance_NN exists_VBZ in_IN failing_VBG myocytes_NNS ._SENT Yeast_NP Two-Hybrid_NP Screening_NP ._SENT |_SYM Yeast_NP two-hybrid_JJ screening_NN using_VBG pBTM-casp3-p12p17m_NN as_IN bait_NN vector_NN was_VBD performed_VBN with_IN a_DT human_JJ heart_NN cDNA_NN library_NN fused_VBD to_TO the_DT Gal4_NP activation_NN domain_NN in_IN the_DT pACT2_JJ plasmid_NP (_( CLONTECH_NP )_) ,_, following_VBG the_DT Hybrid_NP Hunter_NP two-hybrid_JJ system_NN protocol_NN (_( Invitrogen_NP )_) in_IN L40_NP yeast_NN cells_NNS (_( MATa_NP trp1_JJ lue2_JJ his3_NN ade2_NN LYS2::4lexAop-HIS3_NP URA3::8lexAop-lacZ_NP )_) ._SENT A_DT total_NN of_IN 30_CD x_SYM 106_CD independent_JJ clones_NNS were_VBD screened_VBN by_IN selective_JJ growth_NN on_IN Trp-_NP /Leu-_NN /His-_NN /Ura-_NN /Lys-_NN /Ade+_NN synthetic_JJ dropout_NN medium_NN plates_NNS and_CC expression_NN of_IN beta-galactosidase_NN activity_NN ._SENT In_IN Vitro_NP Cleavage_NP of_IN Positive_NP Clone_NP Products_NPS by_IN Recombinant_NP Caspase-3_NP ._SENT |_SYM To_TO construct_VB expression_NN plasmids_NNS for_IN positive_JJ clones_NNS obtained_VBN from_IN the_DT two-hybrid_JJ screening_NN ,_, EcoRI_NP --_: XhoI_NP fragments_NNS of_IN positive_JJ clones_NNS were_VBD inserted_VBN into_IN the_DT EcoRI_NP --_: XhoI_NP cloning_VBG sites_NNS of_IN pYES2_JJ /NT-A_NP plasmid_NP (_( Invitrogen_NP )_) ,_, in_IN which_WDT the_DT sequences_NNS were_VBD under_IN control_NN of_IN the_DT T7_JJ promoter_NN ._SENT Biotinylated_JJ lysine-labeled_JJ proteins_NNS were_VBD prepared_VBN from_IN expression_NN plasmids_NNS by_IN using_VBG a_DT TNT_NP T7_NP Quick_NP Coupled_NP Transcription_NP /Translation_NN System_NP (_( Promega_NP )_) ,_, according_VBG to_TO the_DT manufacturer_NN 's_POS instructions_NNS ._SENT Five_CD microliters_NNS of_IN biotinylated_JJ lysine-labeled_JJ protein_NN were_VBD incubated_VBN for_IN 1_CD hr_NN at_IN 37C_JJ with_IN 15_CD ng_NNS /mul_VBP recombinant_JJ active_JJ caspase-3_NN (_( BD_NP PharMingen_NP )_) and_CC optionally_RB with_IN 25_CD muM_NN caspase-3_NN inhibitor_NN DEVD-fmk_NP (_( fluoromethyl_NN ketone_NN )_) in_IN a_DT TrisCl_NP reaction_NN buffer_NN ,_, pH_NN 7.5_CD (_( 6_CD mM_NP TrisCl_NP ,_, pH_NN 7.5_CD /1.2_CD mM_NP CaCl2_NP /5_CD mM_NP DTT_NP /1.5_CD mM_NP MgCl2_NP /1_CD mM_NP KCl_NP )_) ._SENT Samples_NNS were_VBD size_NN fractionated_VBN by_IN SDS_NP /15_CD %_NN PAGE_NN and_CC blotted_VBD to_TO a_DT nitrocellulose_NN membrane_NN ._SENT Colorimetric_JJ detection_NN of_IN biotinylated_JJ products_NNS was_VBD performed_VBN on_IN blots_NNS with_IN Transcend_NP Colorimetric_NP Translation_NN Detection_NP System_NP (_( Promega_NP )_) ._SENT Site-Directed_NP Mutagenesis_NP and_CC Expression_NP of_IN Mutant_NP Proteins_NPS in_IN COS-7_NP Cells_NP ._SENT |_SYM The_DT coding_VBG sequence_NN of_IN human_JJ wild-type_NN vMLC1_NN was_VBD cloned_VBN into_IN the_DT KpnI_NP --_: XbaI_NP sites_NNS of_IN the_DT gfp-expressing_NN pAdTrack_NN vector_NN ,_, between_IN a_DT non-tissue-specific_JJ cytomegalovirus_NN (_( CMV_NP )_) promoter_NN and_CC a_DT SV40_NP polyadenylation_NN signal_NN ._SENT Site-directed_JJ mutagenesis_NN of_IN the_DT Asp_NP at_IN position_NN 132_CD to_TO Ala_NP (_( D132A_NP )_) and_CC of_IN the_DT Glu_NP at_IN position_NN 135_CD to_TO Ser_NP (_( E135S_NP )_) was_VBD performed_VBN with_IN the_DT QuikChange_NP XL_NP Site-Directed_NP Mutagenesis_NP kit_NN (_( Stratagene_NP )_) ,_, using_VBG the_DT pAdTrack-vMLC1_JJ plasmid_NN and_CC two_CD complementary_JJ oligonucleotides_NNS containing_VBG the_DT desired_VBN mutation_NN ._SENT Mutated_VBN clones_NNS were_VBD identified_VBN by_IN diagnostic_JJ StuI_NP and_CC BsrBI_NP digestion_NN (_( for_IN D132A_NP and_CC E135S_NP ,_, respectively_RB )_) and_CC verified_VBN by_IN sequencing_NP ._SENT For_IN transient_JJ expression_NN of_IN wild-type_NN vMLC1_NN and_CC its_PP$ mutants_NNS vMLC1mD132A_NN and_CC vMLC1mE135S_NNS ,_, COS-7_JJ cells_NNS were_VBD transfected_VBN with_IN pAdTrack-vMLC1_NN or_CC pAdTrack-vMLC1m_NN plasmids_NNS by_IN polycationic_JJ SuperFect_NP Transfection_NP Reagent_NP (_( Qiagen_NP ,_, Valencia_NP ,_, CA_NP )_) ._SENT Forty-eight_NN hours_NNS after_IN transfection_NN ,_, cell_NN protein_NN extracts_VBZ were_VBD prepared_VBN and_CC analyzed_VBN for_IN caspase-3_JJ cleavage_NN by_IN Western_JJ blot_NN ._SENT Antibodies_NNS and_CC Western_NP Blot_NP Analysis_NP ._SENT |_SYM Protein_NP extracts_VBZ from_IN rabbit_NN ventricle_NN or_CC from_IN COS-7_JJ cells_NNS were_VBD prepared_VBN by_IN homogenization_NN in_IN TrisCl_NP reaction_NN buffer_NN ,_, pH_NN 7.5_CD ._SENT To_TO examine_VB the_DT cleavage_NN by_IN caspase-3_NN ,_, 150_CD mug_NN of_IN protein_NN were_VBD incubated_VBN for_IN 1_CD hr_NN at_IN 37C_JJ with_IN different_JJ amounts_NNS of_IN recombinant_JJ human_JJ caspase-3_NN ,_, in_IN the_DT presence_NN or_CC absence_NN of_IN the_DT caspase-3_JJ inhibitor_NN DEVD-fmk_NP (_( 25_CD muM_NN )_) ._SENT After_IN size_NN fractionation_NN by_IN SDS_NP /15_CD %_NN PAGE_NN ,_, proteins_NNS were_VBD electrophoretically_RB transferred_VBN to_TO a_DT nitrocellulose_NN membrane_NN and_CC blots_NNS were_VBD incubated_VBN for_IN 1_CD hr_NN with_IN mouse_NN monoclonal_NN antibodies_NNS against_IN vMLC1_JJ (_( 0.2_CD mug_NN /ml_NN ,_, clone_NN 2c8_JJ ,_, BiosPacific_NP ,_, Emeryville_NP ,_, CA_NP ;_: 1:10_CD dilution_NN ,_, clones_NNS F109.16A12_NP and_CC F109.17A5_NP ,_, Biocytex_NP ,_, Marseilles_NP ,_, France_NP )_) ._SENT Bound_JJ antibodies_NNS were_VBD detected_VBN with_IN horseradish_NN peroxidase-conjugated_JJ antibody_NN against_IN mouse_NN IgG_NP (_( 1:10,000_CD dilution_NN ,_, Sigma_NP )_) and_CC visualized_VBN by_IN chemiluminescence_NN ._SENT Obtained_VBN chemiluminograms_NNS were_VBD evaluated_VBN by_IN densitometric_JJ analysis_NN using_VBG scion_NN image_NN (_( Scion_NP ,_, Frederick_NP ,_, MD_NP )_) ._SENT Determination_NN of_IN Caspase-3_NP Specificity_NP for_IN DFVE_NP ._SENT |_SYM Ac-DFVE-AMC_NP and_CC Ac-DEVD-AMC_NP were_VBD synthesized_VBN by_IN Biosyntan_NP (_( Berlin_NP )_) with_IN a_DT purity_NN of_IN 94_CD %_NN ._SENT Active_JJ recombinant_JJ human_JJ caspase-3_NN (_( BD_NP PharMingen_NP )_) was_VBD added_VBN at_IN a_DT final_JJ concentration_NN of_IN 3_CD nM_NN to_TO a_DT reaction_NN mixture_NN containing_VBG 20_CD mM_NP Hepes_NP ,_, 100_CD mM_NP NaCl_NP ,_, 10_CD mM_NP DTT_NP ,_, 1_CD mM_NP EDTA_NP ,_, 0.1_CD %_NN CHAPS_NP ,_, 10_CD %_NN sucrose_NN (_( pH_NN 7.2_CD )_) ,_, and_CC both_DT substrates_NNS in_IN concentrations_NNS ranging_VBG from_IN 0_CD to_TO 400_CD muM_NN ._SENT After_IN a_DT 10-min_JJ preincubation_NN at_IN 37C_NP ,_, the_DT released_VBN fluorogenic_JJ AMC_NP was_VBD monitored_VBN every_DT second_JJ minute_NN for_IN 20_CD min_NN at_IN 460_CD nm_NN with_IN 380_CD nm_NN excitation_NN ._SENT Km_NN and_CC kcat_NN values_NNS were_VBD determined_VBN from_IN plots_NNS of_IN activity_NN versus_CC substrate_NN concentration_NN ._SENT Absolute_JJ kcat_NN values_NNS were_VBD calculated_VBN using_VBG a_DT standard_JJ curve_NN determined_VBN with_IN AMC_NP ._SENT Construction_NN and_CC Purification_NN of_IN Recombinant_NP Adenovirus_NP ._SENT |_SYM Recombinant_NP (_( E1-_NP and_CC E3-deficient_JJ )_) adenoviruses_NNS (_( Serotype_NP 5_CD )_) carrying_VBG the_DT green_JJ fluorescence_NN protein_NN gfp_NN (_( Adgfp_NP )_) or_CC both_DT gfp_NN and_CC the_DT baculoviral_JJ apoptotic_JJ suppressor_NN p35_NN (_( Adp35_NP )_) were_VBD generated_VBN as_IN described_VBN ._SENT Pacing-Induced_NP Heart_NP Failure_NN and_CC Transcoronary_NP Gene_NP Delivery_NN ._SENT |_SYM Pacemakers_NP were_VBD implanted_VBN into_IN New_NP Zealand_NP White_NP rabbits_NNS ,_, and_CC animals_NNS were_VBD paced_VBN at_IN 340_CD beats_NNS per_IN min_NN for_IN 2_CD weeks_NNS ,_, as_RB described_VBN ._SENT Transcoronary_JJ gene_NN delivery_NN of_IN Adgfp_NP or_CC Adp35_NP (_( 5_CD x_SYM 1010_CD plaque-forming_JJ units_NNS )_) into_IN rabbit_NN myocardium_NN was_VBD performed_VBN at_IN the_DT time_NN ventricular_JJ pacing_VBG was_VBD initiated_VBN ,_, as_RB reported_VBN ._SENT The_DT project_NN was_VBD approved_VBN by_IN the_DT institutional_JJ ethics_NNS review_NN board_NN ._SENT Immunoprecipitation_NN of_IN vMLC1_NN ._SENT |_SYM Left_NP ventricle_NN lysates_NNS from_IN control_NN and_CC 15_CD days_NNS paced_VBD rabbit_NN myocardium_NN were_VBD prepared_VBN by_IN homogenization_NN in_IN denaturing_VBG lysis_NN buffer_NN (_( 50_CD mM_NP TrisCl_NP ,_, pH_NN 7.4_CD /5_CD mM_NP EDTA_NP /1_CD %_NN SDS_NP /10_CD mM_NP DTT_NP /1_CD mM_NP PMSF_NP /2_CD mug/ml_NN leupeptin_NN /15_CD units/ml_NN DNase_NP I_NP )_) ,_, heated_VBN at_IN 95C_NN for_IN 5_CD min_NN ,_, diluted_VBD 1:10_CD with_IN nondenaturing_JJ lysis_NN buffer_NN (_( 50_CD mM_NP TrisCl_NP ,_, pH_NN 7.4_CD /300_CD mM_NP NaCl_NP /5_CD mM_NP EDTA_NP /1_CD %_NN Triton_NP X-100_NP /10_CD mM_NP iodoacetamide_NN /1_CD mM_NP PMSF_NP /2_CD mug/ml_NN leupeptin_NN /0.02_CD %_NN sodium_NN azide_NN )_) ,_, and_CC centrifuged_VBD at_IN 15,000_CD x_NN g_NN for_IN 10_CD min_NN at_IN 4C_JJ ._SENT After_IN dilution_NN to_TO 3.5_CD mg_NN of_IN protein_NN per_IN ml_NN ,_, supernatants_NNS were_VBD precleared_VBN with_IN excess_NN of_IN protein_NN G-Sepharose_NP beads_NNS (_( Sigma_NP )_) and_CC incubated_VBN for_IN 2_CD hr_NN at_IN 4C_JJ with_IN protein_NN G-Sepharose_NP beads_NNS (_( 30_CD mul_NN of_IN beads_NNS per_IN ml_NN lysate_NNS )_) ,_, preconjugated_VBN with_IN 100_CD mug_NN anti-vMLC1_JJ monoclonal_NN antibody_NN (_( clone_NN 2c8_JJ )_) ._SENT Beads_NNS containing_VBG the_DT immunocomplex_NN were_VBD subjected_VBN to_TO SDS_NP /15_CD %_NN PAGE_NN and_CC immunoblotting_NN for_IN vMLC1_NN ._SENT Preparation_NN and_CC Culture_NP of_IN Adult_NP Rabbit_NP Ventricular_NP Myocytes_NP ._SENT |_SYM Single_NP myocytes_NNS were_VBD isolated_VBN from_IN the_DT left_VBN ventricle_NN of_IN control_NN and_CC 15_CD days_NNS paced_VBD failing_VBG rabbits_NNS ,_, and_CC cultured_VBN in_IN modified_JJ M199_NP medium_NN on_IN laminin-precoated_JJ glass_NN slides_NNS ,_, as_RB described_VBN ._SENT Two_CD hours_NNS after_IN plating_NN ,_, cells_NNS were_VBD subjected_VBN to_TO detection_NN of_IN activated_VBN caspase-3_NN ._SENT Activated_VBN Caspase-3_NP Detection_NP and_CC Fluorescence_NP Staining_NP ._SENT |_SYM Activated_JJ caspase-3_NN was_VBD detected_VBN in_IN living_VBG cells_NNS by_IN using_VBG CaspaTag_NP Caspase-3_NP Activity_NP Kit_NP (_( Intergen_NP ,_, Oxford_NP )_) ,_, according_VBG to_TO the_DT manufacturer_NN 's_POS instructions_NNS ._SENT Freshly_RB isolated_VBN ventricular_JJ myocytes_NNS were_VBD incubated_VBN at_IN 37C_JJ (_( 5_CD %_NN CO2_NN )_) with_IN FAM-DEVD-fmk_NP or_CC SR-DEVD-fmk_NP ,_, carboxyfluorescein-_NN or_CC sulforhodamine-labeled_JJ fluoromethyl_NN ketone_NN tetrapeptide_NN inhibitor_NN of_IN caspase-3_NN ._SENT After_IN 1_CD hr_NN incubation_NN ,_, cells_NNS were_VBD washed_VBN ,_, fixed_VBN in_IN 4_CD %_NN paraformaldehyde_NN ,_, permeabilized_VBN in_IN 100_CD %_NN methanol_NN (_( at_IN -20C_NN )_) ,_, and_CC subjected_VBN to_TO Hoechst_NP 33258_CD staining_VBG and_CC either_RB to_TO immunostaining_VBG for_IN vMLC1_JJ /vMLC2_NN (_( ventricular_JJ regulatory_JJ myosin_NN light_NN chain_NN )_) ,_, or_CC to_TO phalloidin_NNS staining_VBG ._SENT vMLCs_NNS were_VBD detected_VBN with_IN mouse_NN monoclonal_NN antibodies_NNS anti-vMLC1_JJ (_( 4_CD mug_NN /ml_NN ,_, clone_NN 2c8_JJ )_) and_CC anti-vMLC2_JJ (_( 1:2_CD dilution_NN ,_, clone_NN F109.3E1_NP ,_, Biocytex_NP )_) ,_, followed_VBN by_IN incubation_NN with_IN Texas_NP red_NN or_CC Cascade_NP blue_JJ goat_NN anti-mouse-IgG_NN conjugate_VB (_( 10_CD mug_NN /ml_NN ,_, Molecular_NP Probes_NP )_) ._SENT Polymerized_VBN actin_NN fibers_NNS were_VBD visualized_VBN by_IN Texas_NP red-phalloidin_NP (_( 3_CD units_NNS /ml_NN ,_, Molecular_NP Probes_NP )_) ._SENT Cell_NN Shortening_NP Experiments_NP ._SENT |_SYM Fractional_NP shortening_NN was_VBD measured_VBN in_IN rabbit_NN adult_NN cardiomyocytes_NNS isolated_VBN from_IN left_JJ ventricle_NN of_IN control_NN and_CC 15_CD days_NNS paced_VBD failing_VBG myocardium_NN ,_, after_IN detection_NN of_IN activated_VBN caspase-3_NN ._SENT Experiments_NNS were_VBD performed_VBN in_IN a_DT temperature-controlled_JJ cuvette_NN (_( 37C_JJ )_) ,_, using_VBG an_DT electro-optical_JJ monitoring_NN system_NN (_( Scientific_NP Instruments_NP ,_, Heidelberg_NP )_) ,_, as_RB described_VBN ._SENT Statistical_NP Analysis_NP ._SENT |_SYM Data_NP represent_VB mean_JJ +-_NN SEM_NP and_CC were_VBD analyzed_VBN by_IN one-way_JJ analysis_NN of_IN variance_NN ,_, followed_VBN by_IN Scheffe_NP post_NN hoc_FW analysis_NN ._SENT Statistical_JJ significance_NN was_VBD accepted_VBN at_IN the_DT level_NN of_IN P_NN <_SYM 0.05_CD ._SENT Identification_NN of_IN vMLC1_NN as_IN Substrate_NP for_IN Caspase-3_NP ._SENT |_SYM In_IN a_DT rabbit_NN model_NN of_IN CHF_NP obtained_VBD by_IN rapid_JJ ventricular_JJ pacing_VBG ,_, we_PP previously_RB demonstrated_VBD that_IN caspase-3_JJ activation_NN is_VBZ associated_VBN with_IN a_DT reduction_NN in_IN contractile_JJ force_NN of_IN failing_VBG myocytes_NNS ._SENT Using_VBG in_IN vivo_JJ transcoronary_JJ adenovirus-mediated_JJ gene_NN delivery_NN of_IN the_DT potent_JJ caspase_NN inhibitor_NN p35_NN ,_, we_PP could_MD correct_VB caspase-3_JJ activation_NN in_IN failing_VBG myocardium_NN with_IN a_DT positive_JJ impact_NN on_IN sarcomeric_JJ organization_NN and_CC contractile_JJ performance_NN ._SENT To_TO better_RBR understand_VB the_DT mechanism_NN that_WDT may_MD cause_VB caspase-mediated_JJ sarcomeric_JJ disarray_NN ,_, we_PP performed_VBD in_IN this_DT study_NN a_DT screening_NN for_IN caspase-3-interacting_VBG proteins_NNS expressed_VBN in_IN the_DT heart_NN ._SENT We_PP used_VBD a_DT modified_JJ yeast_NN two-hybrid_NN system_NN with_IN ,_, as_IN bait_NN vector_NN ,_, the_DT plasmid_NP pBTM-casp3-p12p17m_NN ,_, which_WDT has_VBZ already_RB been_VBN successfully_RB used_VBN to_TO identify_VB gelsolin_NN as_IN a_DT substrate_NN for_IN caspase-3_NN ._SENT Both_DT large_JJ (_( p17_JJ )_) and_CC small_JJ (_( p12_JJ )_) subunits_NN of_IN active_JJ caspase-3_NN were_VBD separately_RB expressed_VBN in_IN yeast_NN at_IN equimolar_JJ ratios_NNS under_IN ADH1_JJ promoters_NNS ._SENT The_DT small_JJ subunit_NN was_VBD fused_VBN to_TO the_DT LexA_NP DNA-binding_NP domain_NN ,_, and_CC a_DT point_NN mutation_NN in_IN the_DT active_JJ site_NN of_IN the_DT enzyme_NN (_( Cys-163_NP ->_NP Ser_NP )_) prevented_VBD proteolytic_JJ cleavage_NN of_IN interacting_VBG substrates_NNS ._SENT The_DT bait_NN plasmid_NN was_VBD cotransfected_VBN into_IN yeast_NN with_IN a_DT human_JJ heart_NN cDNA_NN expression_NN library_NN fused_VBD to_TO the_DT Gal-4_NP activation_NN domain_NN ._SENT By_IN screening_VBG 30_CD million_CD transformants_NNS ,_, we_PP obtained_VBD 125_CD positive_JJ clones_NNS that_WDT were_VBD divided_VBN into_IN 22_CD groups_NNS on_IN the_DT base_NN of_IN inserted_JJ fragment_NN size_NN and_CC restriction_NN enzyme_NN digestion_NN pattern_NN ._SENT DNA_NP sequencing_NP analysis_NN showed_VBD that_IN six_CD of_IN the_DT positive_JJ candidates_NNS encoded_VBD overlapping_JJ C-terminal_JJ parts_NNS (_( clones_NNS 7_CD ,_, 12_CD ,_, and_CC 20_CD )_) or_CC the_DT complete_JJ sequence_NN (_( clones_NNS 3_CD ,_, 9_CD ,_, and_CC 17_CD )_) of_IN vMLC1_NN ._SENT MLC1_NP is_VBZ one_CD of_IN the_DT six_CD polypeptide_NN chains_NNS of_IN the_DT myosin_NN molecule_NN ,_, and_CC is_VBZ proposed_VBN to_TO function_VB as_IN an_DT actin_NN /myosin_NN tether_NN regulating_VBG cross-bridge_NN cycling_NN events_NNS ._SENT In_IN this_DT study_NN we_PP further_RBR analyzed_VBD the_DT vMLC1_JJ clones_NNS ,_, and_CC the_DT others_NNS will_MD be_VB described_VBN elsewhere_RB ._SENT To_TO examine_VB cleavage_NN of_IN vMLC1_NN by_IN caspase-3_NN in_IN vitro_NN ,_, proteins_NNS encoded_VBD by_IN the_DT cDNAs_NNS were_VBD produced_VBN by_IN in_IN vitro_NN transcription_NN /translation-reaction_NN ._SENT As_IN shown_VBN in_IN Fig._NN A_NP ,_, clones_NNS 3_CD ,_, 9_CD ,_, and_CC 17_CD ,_, which_WDT contained_VBD the_DT complete_JJ sequence_NN of_IN human_JJ vMLC1_NN ,_, were_VBD cleaved_VBN by_IN human_JJ recombinant_JJ active_JJ caspase-3_NN ,_, and_CC this_DT cleavage_NN was_VBD blocked_VBN in_IN the_DT presence_NN of_IN its_PP$ tetrapeptide_NN inhibitor_NN DEVD-fmk_NP ,_, suggesting_VBG that_IN vMLC1_NN is_VBZ a_DT possible_JJ substrate_NN for_IN caspase-3_NN ._SENT Immunoblot_NN analysis_NN of_IN protein_NN extracts_VBZ from_IN left_JJ ventricle_NN ,_, incubated_VBN with_IN active_JJ caspase-3_NN ,_, confirmed_VBD this_DT result_NN (_( Fig._NN B_NN )_) ._SENT An_DT ~20-kDa_NN cleavage_NN product_NN for_IN vMLC1_NN was_VBD already_RB evident_JJ with_IN 5_CD ng_NNS /mul_VBP active_JJ caspase-3_NN ._SENT Indeed_RB ,_, other_JJ structurally_RB related_VBN sarcomeric_JJ proteins_NNS ,_, ventricular_JJ vMLC2_NN or_CC beta-myosin_NN heavy_JJ chain_NN ,_, were_VBD not_RB cleaved_VBN ,_, demonstrating_VBG that_DT cleavage_NN of_IN vMLC1_NN was_VBD not_RB due_JJ to_TO a_DT generalized_VBN degradation_NN of_IN proteins_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT Figure_NP 1_CD |_SYM In_IN vitro_NN cleavage_NN of_IN vMLC1_NN by_IN recombinant_JJ active_JJ caspase-3_NN ._SENT In_IN vitro_NN cleavage_NN of_IN vMLC1_NN by_IN recombinant_JJ active_JJ caspase-3_NN ._SENT (_( A_NP )_) SDS_NP /15_CD %_NN PAGE_NN of_IN biotinylated_JJ lysine-labeled_JJ proteins_NNS from_IN three_CD positive_JJ clones_NNS encoding_VBG human_JJ vMLC1_NN after_IN 1_CD hr_NN incubation_NN with_IN 15_CD ng_NNS /mul_VBP human_JJ recombinant_JJ active_JJ caspase-3_NN in_IN presence_NN or_CC absence_NN of_IN 25_CD muM_NN DEVD-fmk_NP ._SENT (_( B_NP )_) Immunoblot_NP analysis_NN of_IN native_JJ vMLC1_JJ cleavage_NN in_IN protein_NN extracts_VBZ from_IN rabbit_NN left_JJ ventricle_NN ,_, incubated_VBN with_IN indicated_JJ concentration_NN of_IN recombinant_JJ active_JJ caspase-3_NN for_IN 1_CD hr_NN ._SENT DEVD-fmk_NP was_VBD applied_VBN in_IN a_DT concentration_NN of_IN 25_CD muM_NN ._SENT Mapping_VBG of_IN the_DT Caspase-3_NP Cleavage_NP Site_NP in_IN vMLC1_NN ._SENT |_SYM To_TO determine_VB caspase-3_JJ cleavage_NN site_NN of_IN vMLC1_NN ,_, purified_VBD human_JJ vMLC1_NN was_VBD incubated_VBN with_IN recombinant_JJ active_JJ enzyme_NN (_( Fig._NN A_NP )_) ._SENT Cleavage_NN of_IN purified_VBN vMLC1_NN resulted_VBN in_IN two_CD fragments_NNS at_IN ~20_JJ kDa_NN and_CC ~5_NN kDa_NN ._SENT Edman_NP sequence_NN analysis_NN of_IN the_DT cleavage_NN products_NNS revealed_VBD that_IN caspase-3_NN cleaved_VBD vMLC1_JJ at_IN E135_NP of_IN the_DT C-terminal_NP motif_NN DFVE135G_NP ,_, which_WDT is_VBZ highly_RB conserved_VBN ._SENT This_DT result_NN was_VBD confirmed_VBN by_IN immunoblot_NN analysis_NN ,_, using_VBG a_DT monoclonal_NN antibody_NN for_IN vMLC1_JJ (_( clone_NN F109.16A12_NP )_) directed_VBD against_IN the_DT sequence_NN V134EGLRV139_NN at_IN the_DT caspase-3_JJ cleavage_NN site_NN ._SENT The_DT antibody_NN detected_VBD the_DT intact_JJ vMLC1_JJ protein_NN but_CC did_VBD not_RB detect_VB either_RB of_IN the_DT two_CD cleavage_NN fragments_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT The_DT mapped_VBN cleavage_NN site_NN corresponds_VBZ to_TO the_DT caspase-3_JJ consensus_NN sequence_NN DXXD_NN ,_, with_IN the_DT exception_NN of_IN substituting_VBG the_DT last_JJ Asp_NP residue_NN for_IN the_DT similar_JJ acidic_JJ Glu_NP residue_NN at_IN position_NN 135_CD ._SENT Caspase-3_NP is_VBZ considered_VBN to_TO have_VB an_DT almost_RB absolute_JJ requirement_NN for_IN an_DT Asp_NP in_IN the_DT P1_NP and_CC P4_NP positions_NNS ._SENT To_TO confirm_VB DFVE135_NP as_IN the_DT caspase-3_JJ cleavage_NN site_NN of_IN vMLC1_JJ ,_, we_PP constructed_VBD mutant_JJ human_JJ vMLC1s_NNS replacing_VBG the_DT Asp_NP in_IN position_NN 132_CD with_IN Ala_NP (_( vMLC1mD132A_NP )_) and_CC the_DT Glu_NP in_IN position_NN 135_CD with_IN Ser_NP (_( vMLC1mE135S_NN )_) by_IN site-directed_JJ mutagenesis_NN ._SENT As_IN shown_VBN in_IN Fig._NN B_NP ,_, wild-type_NN vMLC1_NN was_VBD cleaved_VBN by_IN caspase-3_NN in_IN vitro_NN ._SENT In_IN contrast_NN ,_, both_CC mutant_JJ proteins_NNS exhibited_VBD resistance_NN to_TO cleavage_NN ._SENT This_DT finding_VBG points_NNS to_TO the_DT caspase-3_JJ cleavage_NN site_NN of_IN vMLC1_NN as_IN being_VBG C-terminal_JJ of_IN E135_NP (_( Fig._NN C_NP )_) ._SENT Under_IN the_DT same_JJ conditions_NNS ,_, other_JJ executioner_NN caspases_NNS ,_, such_JJ as_IN caspase-6_NN ,_, -7_CD ,_, and_CC -2_CD ,_, failed_VBN to_TO cleave_VB vMLC1_JJ in_IN vitro_NN ,_, suggesting_VBG that_IN the_DT protein_NN is_VBZ a_DT specific_JJ substrate_NN for_IN caspase-3_NN (_( Fig._NN D_NP )_) ._SENT Figure_NP 2_CD |_SYM Determination_NN of_IN the_DT cleavage_NN site_NN of_IN vMLC1_NN and_CC its_PP$ specificity_NN for_IN caspase-3_NN ._SENT Determination_NN of_IN the_DT cleavage_NN site_NN of_IN vMLC1_NN and_CC its_PP$ specificity_NN for_IN caspase-3_NN ._SENT (_( A_NP )_) Cleavage_NN of_IN purified_VBN human_JJ vMLC1_NN (_( 10_CD mug_NN )_) by_IN recombinant_JJ active_JJ caspase-3_NN (_( 20_CD ng_NNS /mul_NN ,_, 1_CD hr_NN ,_, 37C_NP )_) ,_, analyzed_VBN by_IN SDS_NP /16.5_CD %_NN PAGE_NP and_CC Coomassie_NP blue_JJ staining_VBG ._SENT (_( B_NP )_) Immunoblot_NP analysis_NN of_IN wild-type_NN vMLC1_NN ,_, vMLC1mD132A_NP ,_, and_CC vMLC1mE135S_NN proteins_NNS expressed_VBN in_IN COS-7_JJ cells_NNS ,_, after_IN incubation_NN of_IN the_DT cell_NN extracts_VBZ with_IN recombinant_JJ active_JJ caspase-3_NN (_( 20_CD ng_NNS /mul_NN ,_, 1_CD hr_NN ,_, 37C_JJ )_) ._SENT The_DT first_JJ line_NN (_( c_LS )_) shows_VBZ extracts_VBZ from_IN COS-7_JJ cells_NNS transfected_VBN with_IN control_NN vector_NN plasmid_NN ._SENT Mouse_NN monoclonal_NN antibody_NN directed_VBN against_IN the_DT residues_NNS 1_CD to_TO 8_CD (_( clone_NN F109.17A5_NP )_) was_VBD used_VBN for_IN immunodetection_NN ._SENT (_( C_LS )_) A_DT diagram_NN showing_VBG the_DT caspase-3_JJ cleavage_NN site_NN at_IN the_DT C-terminal_JJ side_NN of_IN E135_NP of_IN human_JJ ,_, rabbit_NN ,_, rat_NN ,_, and_CC chicken_NN vMLC1_NN ._SENT (_( D_NP )_) Immunoblot_NP analysis_NN of_IN vMLC1_JJ cleavage_NN in_IN protein_NN extracts_VBZ from_IN rabbit_NN left_JJ ventricle_NN ,_, incubated_VBN with_IN different_JJ human_JJ recombinant_JJ active_JJ caspases_NNS (_( 25_CD ng_NNS /mul_NN )_) for_IN 1_CD hr_NN ._SENT Because_IN no_DT other_JJ known_VBN targets_NNS for_IN caspase-3_NN contain_VBP the_DT cleavage_NN site_NN DFVE_NP ,_, we_PP characterized_VBD the_DT kinetic_JJ constants_NNS for_IN the_DT DFVE_NP and_CC the_DT classical_JJ DEVD_NN substrates_NNS in_IN a_DT fluorimetric_JJ in_IN vitro_NN assay_NN ._SENT Caspase-3_NP cleaved_VBD efficiently_RB both_DT Ac-DFVE-AMC_NP and_CC Ac-DEVD-AMC_NP with_IN a_DT reproducible_JJ Michaelis_NP --_: Menten_NP kinetic_JJ ._SENT Calculated_JJ Km_NP ,_, kcat_NN ,_, and_CC kcat_NN /Km_NN values_NNS ,_, which_WDT indicate_VBP affinity_NN ,_, turnover_NN ,_, and_CC specificity_NN ,_, respectively_RB ,_, are_VBP presented_VBN in_IN Table_NP ._SENT Other_JJ caspases_NNS did_VBD not_RB cleave_VB the_DT Ac-DFVE-AMC_NP substrate_NN (_( data_NNS not_RB shown_VBN )_) ._SENT Table_NP 1_CD |_SYM Kinetic_JJ constants_NNS for_IN Ac-DFVE-AMC_NP and_CC Ac-DEVD-AMC_NP cleavage_NN by_IN caspase-3_JJ Cleavage_NN of_IN vMLC1_NN by_IN Activated_NP Caspase-3_NP in_IN Vivo_NP ._SENT |_SYM To_TO determine_VB the_DT functional_JJ relevance_NN of_IN vMLC1_JJ cleavage_NN by_IN caspase-3_NN in_IN the_DT heart_NN in_IN vivo_RB ,_, we_PP investigated_VBD the_DT evidence_NN of_IN vMLC1_JJ cleavage_NN products_NNS in_IN extracts_VBZ from_IN rabbit_NN failing_VBG ventricular_JJ myocardium_NN ,_, where_WRB we_PP have_VBP previously_RB documented_VBN a_DT ~6-fold_NN increase_NN in_IN caspase-3_JJ activity_NN ._SENT As_IN shown_VBN in_IN Fig._NN ,_, the_DT intact_JJ vMLC1_JJ protein_NN of_IN ~27_JJ kDa_NNS was_VBD relatively_RB stable_JJ in_IN healthy_JJ control_NN hearts_NNS ._SENT In_IN contrast_NN ,_, a_DT main_JJ ~20-kDa_NN fragment_NN ,_, corresponding_VBG to_TO the_DT N-terminal_JJ cleavage_NN product_NN ,_, was_VBD present_JJ in_IN failing_VBG myocardium_NN (_( %_NN of_IN total_JJ vMLC1_NN :_: 22_CD +-_NN 5_CD %_NN )_) ._SENT Somatic_JJ gene_NN delivery_NN of_IN the_DT irreversible_JJ caspase_NN inhibitor_NN p35_NN into_IN failing_VBG myocardium_NN reduced_VBD vMLC1_JJ cleavage_NN of_IN almost_RB 30_CD %_NN compared_VBN with_IN control_NN adenoviral_NN infection_NN ,_, indicating_VBG that_IN vMLC1_JJ disruption_NN in_IN failing_VBG myocytes_NNS is_VBZ directly_RB mediated_VBN by_IN caspase-3_NN ._SENT The_DT lack_NN of_IN a_DT complete_JJ abolition_NN in_IN vMLC1_JJ cleavage_NN by_IN p35_JJ infection_NN can_MD be_VB due_JJ to_TO the_DT transcoronary_JJ gene_NN transfer_NN protocol_NN used_VBN ,_, which_WDT affects_VBZ only_RB a_DT third_JJ of_IN the_DT whole_NN left_VBD ventricular_JJ myocardium_NN ._SENT Figure_NP 3_CD |_SYM In_IN vivo_JJ cleavage_NN of_IN vMLC1_NN in_IN failing_VBG myocardium_NN and_CC its_PP$ reduction_NN by_IN p35_JJ overexpression_NN ._SENT In_IN vivo_JJ cleavage_NN of_IN vMLC1_NN in_IN failing_VBG myocardium_NN and_CC its_PP$ reduction_NN by_IN p35_JJ overexpression_NN ._SENT Immunoblot_NN analysis_NN after_IN immunoprecipitation_NN of_IN native_JJ vMLC1_JJ cleavage_NN products_NNS in_IN extracts_VBZ of_IN left_VBN ventricle_NN from_IN control_NN healthy_JJ (_( c_LS )_) and_CC failing_VBG (_( CHF_NP )_) rabbit_NN myocardium_NN ,_, after_IN adenoviral_JJ gene_NN delivery_NN of_IN gfp_NN or_CC p35_NN ._SENT Shown_VBN are_VBP representative_JJ data_NNS from_IN one_CD of_IN three_CD animals_NNS in_IN each_DT group_NN ._SENT Bar_NN graph_NN represents_VBZ mean_JJ +-_NN SEM_NP of_IN the_DT percentage_NN of_IN the_DT ~20-kDa_NP N-terminal_NP fragment_NN ._SENT n_NN =_SYM 3_CD ._SENT *_SYM ,_, P_NN <_SYM 0.01_CD ;_: **_SYM ,_, P_NN <_SYM 0.05_CD (_( vs._IN control_NN and_CC CHF+Adgfp_NP ,_, respectively_RB )_) ._SENT Disruption_NN of_IN vMLC1_JJ ,_, Sarcomeric_JJ Integrity_NN ,_, and_CC Contractile_JJ Performance_NN in_IN Failing_NP Myocytes_NP ._SENT |_SYM Myosin_NP is_VBZ the_DT major_JJ component_NN of_IN the_DT thick_JJ filaments_NNS of_IN sarcomeres_NNS ,_, and_CC consists_VBZ of_IN two_CD heavy_JJ chains_NNS (_( alpha_NN and_CC beta_NN )_) ,_, each_DT associated_VBN with_IN two_CD types_NNS of_IN light_JJ chains_NNS ,_, the_DT essential_JJ (_( MLC1_NP )_) and_CC the_DT regulatory_JJ (_( MLC2_NP )_) ._SENT X-ray_VB crystallographic_JJ analyses_NNS demonstrated_VBD that_IN essential_JJ and_CC regulatory_JJ myosin_NN light_NN chains_NNS are_VBP spatially_RB close_JJ ,_, and_CC are_VBP both_DT associated_VBN with_IN the_DT neck_NN region_NN of_IN the_DT myosin_NN heavy_JJ chain_NN globular_JJ head_NN ._SENT To_TO examine_VB whether_IN in_IN failing_VBG myocytes_NNS a_DT morphological_JJ disruption_NN of_IN the_DT organized_JJ vMLC1_NN staining_VBG of_IN A-bands_NNS in_IN sarcomeres_NNS occurred_VBD ,_, and_CC whether_IN it_PP correlated_VBD with_IN caspase-3_JJ activation_NN ,_, single_JJ cardiomyocytes_NNS from_IN control_NN and_CC CHF_NP hearts_NNS were_VBD isolated_VBN ._SENT Fig._NN A_DT shows_VBZ confocal_JJ laser_NN scanning_VBG microscopy_NN of_IN isolated_JJ ventricular_JJ myocytes_NNS after_IN staining_VBG for_IN activated_VBN caspase-3_NN and_CC immunostaining_NN for_IN vMLC1_JJ or_CC vMLC2_JJ ._SENT In_IN cardiomyocytes_NNS isolated_VBN from_IN control_NN hearts_NNS ,_, there_EX was_VBD no_DT evidence_NN of_IN caspase-3_JJ activation_NN ,_, and_CC both_DT myosin_NN light_NN chains_NNS appeared_VBD organized_VBN in_IN the_DT sarcomeric_JJ units_NNS (_( Fig._NN A_NP a_DT --_: b_LS and_CC e_NN --_: f_LS )_) ._SENT In_IN contrast_NN ,_, failing_VBG myocytes_NNS with_IN activated_VBN caspase-3_NN presented_VBD a_DT loss_NN of_IN the_DT characteristic_JJ localization_NN of_IN vMLC1_NN in_IN sarcomeres_NNS ,_, and_CC the_DT A-band_NP vMLC2_NN staining_VBG ,_, which_WDT was_VBD maintained_VBN ,_, showed_VBD a_DT reduced_VBN sarcomeric_JJ organization_NN compared_VBN with_IN that_IN of_IN control_NN cells_NNS (_( Fig._NN A_NP c_SYM --_: d_NN and_CC g_NN --_: h_NN )_) ._SENT Sarcomeric_JJ disarray_NN in_IN failing_VBG cells_NNS presenting_VBG caspase-3_JJ activation_NN was_VBD confirmed_VBN by_IN phalloidin_NN staining_VBG ,_, which_WDT visualizes_VBZ actin_NN filaments_NNS (_( Fig._NN A_DT k_NN --_: l_NN )_) ._SENT Figure_NP 4_CD |_SYM In_IN vivo_JJ cleavage_NN of_IN vMLC1_NN in_IN failing_VBG cardiomyocytes_NNS is_VBZ prevented_VBN by_IN p35_JJ overexpression_NN with_IN positive_JJ impact_NN on_IN myocyte_NN contractile_JJ performance_NN ._SENT In_IN vivo_JJ cleavage_NN of_IN vMLC1_NN in_IN failing_VBG cardiomyocytes_NNS is_VBZ prevented_VBN by_IN p35_JJ overexpression_NN with_IN positive_JJ impact_NN on_IN myocyte_NN contractile_JJ performance_NN ._SENT (_( A_NP )_) Laser_NP scanning_VBG fluorescence_NN microscopy_NN of_IN representative_JJ ventricular_JJ myocytes_NNS isolated_VBN from_IN the_DT anterolateral_JJ wall_NN of_IN control_NN and_CC failing_VBG myocardium_NN ._SENT Green_JJ fluorescence_NN (_( 525_CD nm_NN )_) shows_VBZ activated_VBN caspase-3_NN identified_VBN by_IN FAM-DEVD-fmk_NP ,_, blue_JJ fluorescence_NN (_( 480_CD nm_NN )_) illustrates_VBZ nuclei_NNS by_IN Hoechst_NP 33258_CD ,_, and_CC red_JJ fluorescence_NN (_( 620_CD nm_NN )_) reflects_VBZ vMLC1_JJ (_( a_DT --_: d_LS )_) or_CC vMLC2_JJ (_( e_SYM --_: h_NN )_) ,_, or_CC polymeric_JJ actin_NN by_IN phalloidin_NN staining_VBG (_( i_NP --_: l_NN )_) ._SENT (_( Scale_VB bars_NNS =_SYM 5_CD mum_NN ._SENT )_) One_CD hundred_CD cells_NNS isolated_VBN from_IN three_CD animals_NNS were_VBD analyzed_VBN in_IN each_DT group_NN ._SENT (_( B_NP )_) Representative_NP ventricular_JJ myocytes_NNS isolated_VBN from_IN failing_VBG myocardium_NN after_IN in_IN vivo_JJ infection_NN with_IN Adp35_NP and_CC visualized_VBN by_IN laser_NN scanning_VBG fluorescence_NN microscopy_NN ._SENT Green_JJ fluorescence_NN (_( 503_CD nm_NN )_) identifies_VBZ gfp_NN and_CC shows_VBZ Adp35-infected_JJ cells_NNS ,_, red_JJ fluorescence_NN (_( 580_CD nm_NN )_) reflects_VBZ activated_VBN caspase-3_NN labeled_VBN by_IN SR-DEVD-fmk_NP ,_, and_CC blue_JJ fluorescence_NN (_( 423_CD nm_NN )_) illustrates_VBZ vMLC1_JJ ._SENT (_( Scale_VB bars_NNS =_SYM 5_CD mum_NN ._SENT )_) Bar_NP graphs_NNS represent_VBP the_DT percentage_NN of_IN cells_NNS with_IN organized_JJ (_( white_JJ pattern_NN )_) or_CC destroyed_VBN (_( black_JJ pattern_NN )_) vMLC1_NN staining_VBG in_IN the_DT p35-infected_JJ and_CC uninfected_JJ groups_NNS ._SENT One_CD hundred_CD fifty_CD myocytes_NNS isolated_VBN from_IN three_CD animals_NNS were_VBD analyzed_VBN in_IN each_DT group_NN ._SENT (_( C_NP )_) Contraction_NN amplitude_NN under_IN basal_JJ conditions_NNS and_CC isoproterenol_NN stimulation_NN (_( 10-8_CD M_NN )_) measured_VBN in_IN single_JJ left_JJ ventricle_NN myocytes_NNS ._SENT White_JJ columns_NNS ,_, cells_NNS from_IN control_NN myocardium_NN ;_: gray_JJ columns_NNS ,_, cells_NNS from_IN failing_VBG myocardium_NN negative_JJ for_IN activated_VBN caspase-3_NN ;_: black_JJ columns_NNS ,_, cells_NNS from_IN failing_VBG myocardium_NN positive_JJ for_IN activated_VBN caspase-3_NN ;_: hatched_VBN columns_NNS ,_, cells_NNS from_IN failing_VBG myocardium_NN expressing_VBG p35_NN ._SENT Data_NNS are_VBP expressed_VBN as_IN mean_JJ +-_NN SEM_NP ._SENT n_NN =_SYM 40_CD cells_NNS from_IN three_CD animals_NNS in_IN each_DT group_NN ._SENT *_SYM ,_, P_NN <_SYM 0.005_CD ;_: **_SYM ,_, P_NN <_SYM 0.001_CD [_SYM in_IN comparison_NN with_IN control_NN or_CC caspase-3-positive_JJ failing_VBG cells_NNS (_( basal_JJ ,_, isoproterenol_NN 10-8_CD M_NN )_) ]_SYM ._SENT We_PP have_VBP recently_RB demonstrated_VBN that_IN adenoviral_JJ overexpression_NN of_IN p35_NN in_IN vivo_JJ preserves_NNS sarcomeric_JJ structure_NN and_CC reconstitutes_VBZ contractile_JJ performance_NN of_IN failing_VBG cardiomyocytes_NNS ._SENT Fig._NN B_NN illustrates_VBZ laser_NN scanning_VBG fluorescence_NN images_NNS of_IN representative_JJ single_JJ ventricular_JJ myocytes_NNS isolated_VBN from_IN failing_VBG myocardium_NN infected_VBN with_IN bicistronic_JJ Ad-p35_NP (_( 5_CD x_SYM 1010_CD plaque-forming_JJ units_NNS )_) and_CC stained_VBN for_IN active_JJ caspase-3_NN and_CC vMLC1_JJ ._SENT The_DT typical_JJ vMLC1_NN staining_VBG was_VBD markedly_RB destroyed_VBN in_IN almost_RB 80_CD %_NN of_IN the_DT uninfected_JJ failing_VBG cells_NNS ,_, which_WDT presented_VBD activated_VBN caspase-3_NN (_( Fig._NN B_NP d_SYM --_: f_LS ,_, and_CC adjacent_JJ bar_NN graph_NN )_) ._SENT On_IN the_DT contrary_NN ,_, in_IN failing_VBG myocytes_NNS expressing_VBG the_DT caspase_JJ inhibitor_NN there_EX was_VBD no_DT evidence_NN of_IN caspase-3_JJ activation_NN and_CC in_IN 89_CD %_NN of_IN the_DT analyzed_VBN cells_NNS vMLC1_NN was_VBD localized_VBN in_IN the_DT A-bands_NNS of_IN the_DT sarcomeric_JJ units_NNS (_( Fig._NN B_NN a_DT --_: c_LS ,_, and_CC adjacent_JJ bar_NN graph_NN )_) ._SENT Single-cell_NN shortening_NN experiments_NNS in_IN failing_VBG cardiomyocytes_NNS showed_VBD a_DT reduction_NN of_IN basal_JJ and_CC isoproterenol-stimulated_JJ contraction_NN correlated_VBN to_TO the_DT amount_NN of_IN caspase-3_JJ activation_NN in_IN the_DT cytosol_NN of_IN the_DT failing_VBG cells_NNS (_( Fig._NN C_NP )_) ._SENT Furthermore_RB ,_, blockade_NN of_IN caspase-3_JJ activity_NN by_IN expression_NN of_IN p35_NN restored_VBN contractile_JJ performance_NN of_IN failing_VBG myocytes_NNS (_( Fig._NN C_NP )_) ._SENT Adenoviral_JJ infection_NN did_VBD not_RB alter_VB caspase-3_JJ activation_NN ,_, vMLC1_JJ staining_VBG ,_, or_CC shortening_VBG characteristics_NNS of_IN the_DT cells_NNS ._SENT In_IN this_DT study_NN we_PP used_VBD a_DT modified_JJ yeast_NN two-hybrid_NN system_NN to_TO screen_VB for_IN caspase-3-interacting_VBG proteins_NNS of_IN the_DT cardiac_JJ cytoskeleton_NN ._SENT We_PP identified_VBD vMLC1_JJ as_IN a_DT target_NN for_IN caspase-3_NN ,_, and_CC demonstrated_VBD that_IN its_PP$ cleavage_NN in_IN failing_VBG myocardium_NN in_IN vivo_JJ is_VBZ associated_VBN with_IN a_DT morphological_JJ disruption_NN of_IN the_DT organized_JJ vMLC1_NN staining_VBG of_IN sarcomeres_NNS ._SENT Furthermore_RB ,_, caspase-3_JJ inhibition_NN by_IN adenoviral_JJ overexpression_NN of_IN p35_NN prevented_VBD vMLC1_JJ cleavage_NN with_IN a_DT positive_JJ functional_JJ effect_NN on_IN contractility_NN ._SENT Interestingly_RB ,_, vMLC1_NN is_VBZ cleaved_VBN by_IN caspase-3_NN at_IN a_DT noncanonical_JJ cleavage_NN site_NN ,_, DFVE_NP ,_, that_WDT has_VBZ neither_RB been_VBN described_VBN earlier_RBR in_IN other_JJ substrates_NNS nor_CC identified_VBN as_IN a_DT possible_JJ caspase-3_NN cleavage_NN site_NN in_IN combinatorial_JJ approaches_NNS by_IN using_VBG synthetic_JJ tetrapeptide_NN substrates_NNS ._SENT It_PP is_VBZ widely_RB accepted_VBN that_IN caspases_NNS are_VBP "_`` aspases_NNS ,_, "_'' enzymes_NNS cleaving_VBG substrates_NNS carboxyl-terminal_JJ to_TO an_DT Asp_NP residue_NN ,_, and_CC that_DT caspase-3_JJ consensus_NN motif_NN is_VBZ DXXD_JJ ._SENT However_RB ,_, recent_JJ evidence_NN indicates_VBZ that_IN caspase-9_NP and_CC DRONC_NP ,_, a_DT Drosophila_NP caspase_NN ,_, show_NN activity_NN toward_IN sites_NNS with_IN Glu_NP and_CC Asp_NP residues_NNS at_IN the_DT P1_JJ position_NN ._SENT Furthermore_RB ,_, cleavage_NN of_IN the_DT transcription_NN factor_NN Max_NP by_IN caspase-5_NN ,_, of_IN tumor_NN necrosis_NN factor_NN receptor-I_NNS by_IN caspase-7_JJ ,_, and_CC of_IN lens_NN connexin_NN 45.6_CD by_IN caspase-3_NN have_VBP also_RB been_VBN identified_VBN carboxy-terminal_JJ to_TO a_DT Glu_NP ._SENT These_DT findings_NNS suggest_VBP that_IN the_DT specificity_NN of_IN at_IN least_JJS some_DT caspases_NNS might_MD be_VB more_RBR complex_JJ than_IN implied_VBN previously_RB by_IN studies_NNS with_IN small_JJ synthetic_JJ peptides_NNS ._SENT Our_PP$ data_NNS clearly_RB confirm_VBP that_IN the_DT proposed_VBN requirement_NN of_IN caspase-3_NN for_IN Asp_NP in_IN the_DT P1_JJ position_NN is_VBZ not_RB absolute_JJ ._SENT Kinetic_JJ constants_NNS Km_NP ,_, kcat_NN ,_, and_CC kcat_NN /Km_NN measured_VBN for_IN the_DT synthetic_JJ tetrapeptides_NNS Ac-DFVE-AMC_NP and_CC Ac-DEVD-AMC_NP in_IN vitro_NP showed_VBD that_IN caspase-3_NN has_VBZ a_DT cleavage_NN preference_NN for_IN the_DT classical_JJ site_NN over_IN the_DT noncanonical_JJ ._SENT However_RB ,_, the_DT differences_NNS in_IN enzyme-substrate_JJ affinity_NN ,_, turnover_NN ,_, and_CC specificity_NN are_VBP in_IN the_DT range_NN of_IN those_DT described_VBN for_IN other_JJ caspase_NN --_: substrate_NN interactions_NNS ._SENT Because_IN of_IN the_DT high_JJ substrate_NN /enzyme_NN ratio_NN for_IN vMLC1_NN and_CC caspase-3_NN in_IN cardiac_JJ myocytes_NNS ,_, a_DT lower_JJR cleavage_NN specificity_NN may_MD serve_VB as_IN a_DT physiological_JJ protection_NN against_IN a_DT massive_JJ protein_NN disruption_NN by_IN minimal_JJ caspase-3_NN activation_NN ._SENT Moreover_RB ,_, other_JJ caspases_NNS did_VBD not_RB cleave_VB either_RB the_DT native_JJ vMLC1_NN (_( Fig._NN D_NP )_) or_CC the_DT DFVE_NP peptide_NN ,_, indicating_VBG that_IN the_DT atypical_JJ vMLC1_JJ cleavage_NN site_NN is_VBZ strictly_RB caspase-3-specific_JJ ._SENT In_IN a_DT recent_JJ study_NN ,_, Communal_NP et_FW al._FW examined_VBN in_IN vitro_NN the_DT cleavage_NN of_IN cardiac_JJ myofibrillar_JJ proteins_NNS by_IN caspase-3_NN ._SENT The_DT authors_NNS reported_VBD that_IN active_JJ caspase-3_JJ targets_NNS alpha-actin_NN ,_, alpha-actinin_NN ,_, and_CC troponin_NN T_NN ,_, with_IN consequences_NNS for_IN myocyte_NN function_NN ._SENT In_IN our_PP$ yeast_NN two-hybrid_NN screening_NN ,_, one_CD of_IN the_DT 22_CD positive_JJ candidates_NNS encoded_VBD the_DT C_NP terminus_NN of_IN troponin_NN T_NN ,_, but_CC neither_RB the_DT protein_NN obtained_VBN by_IN in_IN vitro_NN transcription_NN /translation-reaction_NN nor_CC the_DT native_JJ protein_NN in_IN ventricular_JJ extracts_VBZ was_VBD cleaved_VBN by_IN recombinant_JJ active_JJ caspase-3_NN ._SENT Similarly_RB ,_, we_PP did_VBD not_RB detect_VB any_DT cleavage_NN product_NN for_IN alpha-sarcomeric_JJ actin_NN in_IN cardiac_JJ lysates_NNS incubated_VBN with_IN the_DT active_JJ enzyme_NN (_( data_NNS not_RB shown_VBN )_) ._SENT These_DT discrepancies_NNS could_MD be_VB due_JJ to_TO the_DT differing_VBG cleavage_NN reaction_NN conditions_NNS in_IN vitro_NN or_CC to_TO different_JJ antibody_NN sensitivity_NN ._SENT In_IN a_DT rabbit_NN model_NN of_IN CHF_NP ,_, we_PP have_VBP previously_RB demonstrated_VBN that_IN caspase_NN activation_NN contributes_VBZ to_TO disease_NN progression_NN and_CC influences_VBZ contractile_JJ performance_NN of_IN failing_VBG ventricular_JJ myocytes_NNS by_IN destroying_VBG sarcomeric_JJ structure_NN ._SENT It_PP is_VBZ plausible_JJ that_IN numerous_JJ combined_JJ biochemical_JJ pathways_NNS are_VBP responsible_JJ for_IN caspase-mediated_JJ dysfunction_NN and_CC sarcomeric_JJ disarray_NN of_IN failing_VBG cardiac_JJ myocytes_NNS ,_, and_CC that_IN several_JJ components_NNS of_IN the_DT myofilaments_NNS can_MD directly_RB be_VB disrupted_VBN by_IN caspase-3_NN ._SENT In_IN this_DT study_NN ,_, we_PP showed_VBD that_IN vMLC1_NN is_VBZ cleaved_VBN by_IN activated_VBN caspase-3_NN in_IN failing_VBG myocardium_NN in_IN vivo_JJ and_CC its_PP$ cleavage_NN can_MD be_VB blocked_VBN by_IN p35_JJ overexpression_NN with_IN functional_JJ consequences_NNS on_IN contractility_NN ._SENT These_DT findings_NNS support_VBP the_DT notion_NN that_IN this_DT sarcomeric_JJ protein_NN is_VBZ a_DT target_NN for_IN caspase-3_NN and_CC plays_VBZ a_DT central_JJ role_NN in_IN the_DT setting_NN of_IN experimental_JJ heart_NN failure_NN obtained_VBN by_IN rapid_JJ ventricular_JJ pacing_VBG ._SENT Generation_NN of_IN a_DT mouse_NN model_NN carrying_VBG a_DT cleavage-resistant_JJ vMLC1_NN by_IN cardiac-specific_JJ knock-in_NN techniques_NNS would_MD specifically_RB allow_VB evaluation_NN of_IN the_DT importance_NN of_IN vMLC1_JJ proteolysis_NN in_IN cardiac_JJ apoptosis_NN ._SENT A_DT lot_NN of_IN data_NNS suggests_VBZ that_IN myosin_NN light_NN chains_NNS are_VBP important_JJ for_IN cardiac_JJ and_CC skeletal_JJ muscle_NN function_NN ._SENT Removing_VBG MLCs_NNS from_IN chicken_NN skeletal_JJ muscle_NN myosin_NN reduces_VBZ the_DT velocity_NN of_IN actin_NN filament_NN movement_NN by_IN 90_CD %_NN in_IN an_DT in_IN vitro_NP motility_NN assay_NN ._SENT Furthermore_RB ,_, MLC2_JJ removal_NN has_VBZ little_JJ effect_NN on_IN isometric_JJ force_NN ,_, whereas_IN MLC1_JJ removal_NN reduces_VBZ the_DT isometric_JJ force_NN by_IN over_RB 50_CD %_NN ._SENT Mutations_NNS in_IN the_DT human_JJ essential_JJ light_NN chain_NN (_( Met-149_NP ->_NP Val_NP )_) or_CC regulatory_JJ light_JJ chain_NN (_( Glu-22_NP ->_NP Lys_NP ,_, Pro-94_NP ->_NP Arg_NP )_) of_IN myosin_NN are_VBP associated_VBN with_IN rare_JJ variants_NNS of_IN inherited_JJ cardiac_JJ hypertrophy_NN ,_, characterized_VBN by_IN midventricular_JJ cavity_NN obstruction_NN ,_, and_CC correlate_VBP with_IN disruption_NN of_IN the_DT stretch_JJ activation_NN response_NN of_IN the_DT cardiac_JJ papillary_JJ muscles_NNS ._SENT In_IN the_DT human_JJ heart_NN ,_, two_CD different_JJ essential_JJ myosin_NN light_JJ chain_NN isoforms_NNS exist_VBP :_: (_( i_NP )_) an_DT atrial_JJ specific_JJ isoform_NN (_( aMLC1_JJ ,_, atrial_JJ essential_JJ myosin_NN light_NN chain_NN )_) ,_, which_WDT is_VBZ expressed_VBN in_IN the_DT fetal_JJ heart_NN and_CC decreases_NNS to_TO undetectable_JJ levels_NNS during_IN early_JJ postnatal_JJ development_NN in_IN the_DT ventricle_NN ,_, but_CC persists_VBZ in_IN the_DT atrium_NN for_IN the_DT whole_JJ life_NN ,_, and_CC (_( ii_NNS )_) a_DT ventricular_JJ specific_JJ isoform_NN (_( vMLC1_JJ )_) ,_, which_WDT is_VBZ the_DT same_JJ isoform_NN present_NN in_IN adult_JJ slow_JJ skeletal_JJ muscle_NN ._SENT The_DT reexpression_NN of_IN aMLC1_NN in_IN adult_JJ human_JJ ventricles_NNS has_VBZ been_VBN reported_VBN in_IN patients_NNS with_IN ischemic_JJ or_CC dilative_JJ cardiomyopathy_NN ._SENT Interestingly_RB ,_, in_IN such_JJ patients_NNS with_IN end-stage_NN heart_NN failure_NN caspase-3_NN activation_NN has_VBZ also_RB been_VBN documented_VBN ._SENT The_DT isoform_NN shift_NN vMLC1_JJ ->_JJ aMLC1_JJ correlates_NNS with_IN an_DT increase_NN in_IN cross-bridge_NN cycling_NN kinetics_NNS ,_, as_RB measured_VBN in_IN skinned_JJ fibers_NNS derived_VBN from_IN the_DT diseased_JJ muscle_NN ._SENT Postsurgical_JJ return_NN to_TO a_DT normal_JJ hemodynamic_JJ state_NN decreases_VBZ aMLC1_JJ expression_NN in_IN these_DT patients_NNS ._SENT The_DT functional_JJ significance_NN of_IN this_DT isoform_NN switch_NN is_VBZ not_RB completely_RB clear_JJ ,_, but_CC may_MD be_VB a_DT direct_JJ compensatory_JJ mechanism_NN to_TO caspase-3-induced_JJ vMLC1_JJ cleavage_NN ,_, triggered_VBD when_WRB the_DT heart_NN attempts_VBZ to_TO maintain_VB normal_JJ cardiac_JJ function_NN ._SENT Taken_VBN together_RB ,_, these_DT data_NNS clearly_RB illustrate_VBP that_IN minute_JJ changes_NNS in_IN vMLC1_JJ structure_NN or_CC composition_NN can_MD have_VB a_DT dramatic_JJ impact_NN on_IN myocyte_NN function_NN and_CC heart_NN contractility_NN ._SENT The_DT molecular_JJ mechanism_NN for_IN MLC1_NP to_TO affect_VB the_DT cross-bridge_NN kinetics_NN seems_VBZ to_TO reside_VB in_IN its_PP$ Ala-_NP and_CC Pro-rich_NP extended_VBD N_NP terminus_NN ,_, which_WDT has_VBZ been_VBN shown_VBN to_TO interact_VB with_IN the_DT C_NP terminus_NN of_IN actin_NN ._SENT The_DT extended_JJ MLC1_NP N_NP terminus_NN may_MD provide_VB a_DT tether_NN between_IN the_DT myosin_NN and_CC actin_NN filaments_NNS ,_, serving_VBG to_TO position_VB the_DT two_CD filament_NN systems_NNS for_IN cross-bridge_NN interaction_NN and_CC to_TO amplify_VB small_JJ movements_NNS of_IN the_DT myosin_NN globular_JJ head_NN ._SENT The_DT MLC1_NP C_NP terminus_NN anchors_VBZ the_DT protein_NN to_TO the_DT myosin_NN globular_JJ head_NN ._SENT One_PP could_MD speculate_VB that_DT destruction_NN of_IN vMLC1_NN at_IN the_DT C-terminal_JJ motif_NN DFVE135G_NN by_IN activated_VBN caspase-3_NN may_MD alter_VB myosin_NN /actin_NN cross-bridge_NN interactions_NNS by_IN modifying_VBG myosin_NN head_NN stability_NN and_CC thereby_RB lead_VB to_TO reduced_VBN force_NN transmission_NN ._SENT In_IN this_DT study_NN ,_, we_PP have_VBP demonstrated_VBN that_IN vMLC1_NN is_VBZ a_DT cellular_JJ target_NN for_IN caspase-3_NN ._SENT vMLC1_NN is_VBZ cleaved_VBN ,_, and_CC its_PP$ localization_NN in_IN sarcomeres_NNS is_VBZ partially_RB lost_VBN in_IN failing_VBG cardiomyocytes_NNS ,_, presenting_VBG caspase-3_JJ activation_NN and_CC reduced_VBD contractile_JJ performance_NN ._SENT Adenoviral_JJ expression_NN of_IN the_DT caspase_NN inhibitor_NN p35_NN rescued_VBD the_DT myopathic_JJ phenotype_NN of_IN the_DT cells_NNS ._SENT It_PP is_VBZ plausible_JJ that_IN vMLC1_JJ disruption_NN could_MD alter_VB the_DT stiffness_NN of_IN the_DT myosin_NN neck_NN region_NN and_CC therefore_RB reduce_VB the_DT full_JJ range_NN of_IN myosin_NN movement_NN during_IN contraction_NN ._SENT Our_PP$ findings_NNS suggest_VBP that_IN caspase-3-mediated_JJ cleavage_NN of_IN vMLC1_NN may_MD represent_VB a_DT molecular_JJ mechanism_NN contributing_VBG to_TO the_DT deterioration_NN of_IN cardiac_JJ function_NN before_IN myocyte_NN cell_NN death_NN ._SENT Abbreviations_NNS :_: CHF_NP =_SYM congestive_JJ heart_NN failure_NN fluoromethyl_NN ketone_NN ventricular_JJ essential_JJ myosin_NN light_NN chain_NN ventricular_JJ regulatory_JJ myosin_NN light_NN chain_NN 